The Right to Try Act, if signed by the President, will give terminal cancer patients access to experimental drugs, especially when other treatment options have been exhausted.
Osimertinib demonstrated clinically meaningful progression-free survival benefit in EGFR mutation–positive NSCLC compared with current standard of care.
A recent analysis of 360 primary breast cancer genomes has identified some potentially important cancer-driving mutations found within noncoding genomic regions.
A new study indicates that patients with primary immunodeficiency diseases may be at a much higher risk for certain cancers, especially lymphoma.
Researchers in Spain discovered a strange side effect of PD-L1 immunotherapy in some NSCLC patients—hair repigmentation—that may be a good response marker for this treatment.
In this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.
Comprehensive sequencing for all breast cancer genes may provide complete relevant genetic information for Ashkenazi Jewish patients.
Acalabrutinib has been granted FDA Breakthrough Therapy Designation for the treatment of patients with mantle cell lymphoma who have relapsed or have received at least one prior therapy.
A 45-year-old woman presents with a lesion near the pancreas. What is your diagnosis?
Researchers have discovered new associations between breast and ovarian cancer and genes that had not been previously detected, and which may help guide treatment decisions in the future.
A 17-year-old boy presents with a lesion in the face. What is your diagnosis?
A large genomic sequencing analysis of patients with T-ALL revealed a new landscape of mutations that may inform future treatment strategies.
A 32-year-old man presents with a mass in the right thigh. What is your diagnosis?
A 27-year-old man presents with a lesion in the right side of his neck. What is your diagnosis?
Researchers have identified two distinct stem cell–like populations from which relapse can arise in AML patients, which may help clinicians identify who will and won't respond to standard chemotherapy.